JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

Home・Aandelen Lijst・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Gesloten

SectorGezondheidszorg

36.48 -0.92

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

36.3

Max

36.63

Belangrijke statistieken
By Trading Economics
Inkomsten	11M 51M
Verkoop	39M 239M
K/W Sectorgemiddelde	11.786 90.422
EPS	1.08
Winstmarge	21.242
Werknemers	268
EBITDA	14M 73M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+19.8% upside

Dividenden
By Dow Jones
Volgende Winsten	24 feb 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	464M 2.2B
Vorige openingsprijs	37.4
Vorige sluitingsprijs	36.48

Nieuwssentiment

By Acuity

38%

62%

92 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

29.8 / N/A Steun & Weerstand

Harmony Biosciences Holdings Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 feb 2026, 23:59 UTC

Marktinformatie

Oil Prices Fall Amid Signs of U.S.-Iran Negotiations -- Market Talk

1 feb 2026, 23:47 UTC

Marktinformatie

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

1 feb 2026, 23:44 UTC

Marktinformatie

Gold Falls as Markets Further Price in Warsh-Led Fed -- Market Talk

1 feb 2026, 12:47 UTC

Acquisities, Fusies, Overnames

KKR-Led Group Set to Buy Singapore Data-Center Firm Valued at Over $10 Billion -- Update

1 feb 2026, 03:02 UTC

Acquisities, Fusies, Overnames

KKR-Led Group Set to Buy Singapore Data-Center Firm Valued at Over $10 Billion

1 feb 2026, 03:01 UTC

Acquisities, Fusies, Overnames

KKR Consortium Currently Owns Near 20% Stake in STT GDC

1 feb 2026, 03:01 UTC

Acquisities, Fusies, Overnames

KKR Consortium Acquiring Remaining Stake in STT GDC With Singtel, Sources Say

31 jan 2026, 18:48 UTC

Acquisities, Fusies, Overnames

Negotiations Over $100B OpenAI, Nvidia Deal Stall -- Update

31 jan 2026, 16:40 UTC

Winsten

'All Boats Are Rising' in Data and Memory, Says Western Digital's CFO. Just Look at the Stocks. -- Barrons.com

31 jan 2026, 09:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

30 jan 2026, 23:47 UTC

Acquisities, Fusies, Overnames

Negotiations Over $100B OpenAI, Nvidia Deal Stall -- WSJ

30 jan 2026, 23:47 UTC

Acquisities, Fusies, Overnames

Nvidia, OpenAI in Talks to Revise Nature of Broader Partnership, Sources Say -- WSJ

30 jan 2026, 23:47 UTC

Acquisities, Fusies, Overnames

Nvidia CEO Jensen Huang Has Privately Told Colleagues That Deal Is Non-Binding, Sources Say -- WSJ

30 jan 2026, 23:47 UTC

Acquisities, Fusies, Overnames

Nvidia's Huang Has Privately Criticized OpenAI's Business Strategy, Sources Say -- WSJ

30 jan 2026, 23:47 UTC

Acquisities, Fusies, Overnames

OpenAI, Nvidia Deal Talks Stalled in Recent Months, Sources Say -- WSJ

30 jan 2026, 23:47 UTC

Acquisities, Fusies, Overnames

Nvidia's Huang Expressed Concerns Over Competition OpenAI Faces From Anthropic, Google, Sources Say -- WSJ

30 jan 2026, 23:47 UTC

Acquisities, Fusies, Overnames

Nvidia Weighing Equity Investment of Tens of Billions of Dollars Into OpenAI, Sources Say -- WSJ

30 jan 2026, 23:47 UTC

Acquisities, Fusies, Overnames

Negotiations Over $100B OpenAI, Nvidia Deal Stall, Sources Say -- WSJ

30 jan 2026, 23:41 UTC

Marktinformatie

Deckers Outdoor Seen as Undervalued -- Market Talk

30 jan 2026, 23:12 UTC

Acquisities, Fusies, Overnames

Supreme Court of British Columbia Approves Fortescue Purchase of Alta Copper

30 jan 2026, 22:20 UTC

Winsten

Verizon Posts Strong Subscriber Gains Under New CEO -- WSJ

30 jan 2026, 22:10 UTC

Marktinformatie

Disney CEO's Exit Plan Marks Abrupt End to Messy Succession -- Market Talk

30 jan 2026, 21:50 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

30 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

30 jan 2026, 21:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

30 jan 2026, 21:42 UTC

Winsten

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

30 jan 2026, 21:36 UTC

Winsten

GE Aerospace and GE Vernova Issue Their Annual Reports. They Contain Messages for Investors. -- Barrons.com

30 jan 2026, 21:33 UTC

Winsten

Tesla Stock Rebounds From Earnings Dip. SpaceX Is Helping. -- Barrons.com

30 jan 2026, 20:42 UTC

Winsten

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

30 jan 2026, 20:37 UTC

Acquisities, Fusies, Overnames

Why a Ruling Over CK Hutchison's Panama Canal Ports Matters -- and What's Next -- WSJ

Peer Vergelijking

Prijswijziging

Harmony Biosciences Holdings Inc Prognose

Koersdoel

By TipRanks

19.8% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 43.75 USD 19.8%

Hoogste 55 USD

Laagste 32 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Harmony Biosciences Holdings Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Harmony Biosciences Holdings Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

29.8 / N/ASteun & Weerstand

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

92 / 352 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.